ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Session » RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

Date: Saturday, November 7, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM
Abstract Number: 0814
“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic
9:00AM-11:00AM
Abstract Number: 0798
A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (Abrilada™), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92
9:00AM-11:00AM
Abstract Number: 0800
A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0828
Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study
9:00AM-11:00AM
Abstract Number: 0826
Clinical Responses and Patient Flow over 2 Years of Treatment with Abatacept, Including Dose De-Escalation, in Patients with Early, MTX-Naïve, ACPA+ RA: Results from a Phase IIIb Study
9:00AM-11:00AM
Abstract Number: 0827
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
9:00AM-11:00AM
Abstract Number: 0809
Comparative Effectiveness of Intravenous Golimumab vs Dose-Escalated Infliximab in a Real World Population of Rheumatoid Arthritis Patients: 52-Week Data from the AWARE Study
9:00AM-11:00AM
Abstract Number: 0797
Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis
9:00AM-11:00AM
Abstract Number: 0830
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 0822
Effectiveness After Transition to SB4 (Brenzys, Etanercept Biosimilar) versus Continuation of Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity: A Prospective Multinational Multicenter Observational Study
9:00AM-11:00AM
Abstract Number: 0799
Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD
9:00AM-11:00AM
Abstract Number: 0818
Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0804
Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands
9:00AM-11:00AM
Abstract Number: 0821
Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry
9:00AM-11:00AM
Abstract Number: 0820
High Remission Rates in RA – Real Life Data from Bariticinib
9:00AM-11:00AM
Abstract Number: 0806
Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy
9:00AM-11:00AM
Abstract Number: 0823
Identifying Physician-Perceived Barriers to a Pragmatic Treatment Trial in Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0815
Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 0829
International Comparison of Japanese and US Cross Country Utilization of RA Medications
9:00AM-11:00AM
Abstract Number: 0834
Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry
9:00AM-11:00AM
Abstract Number: 0810
Long Term Remission Rates from a Biologic Clinic: 12 Year Real World Data
9:00AM-11:00AM
Abstract Number: 0811
Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab
9:00AM-11:00AM
Abstract Number: 0833
Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics
9:00AM-11:00AM
Abstract Number: 0832
PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany
9:00AM-11:00AM
Abstract Number: 0802
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness
9:00AM-11:00AM
Abstract Number: 0803
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety
9:00AM-11:00AM
Abstract Number: 0812
Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US
9:00AM-11:00AM
Abstract Number: 0807
Safety of Biologic & Targeted Therapies Among Elderly Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 0825
Sex Differences in the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis Patients: A Post Hoc Analysis of Phase 3 and Long-Term Extension Trials
9:00AM-11:00AM
Abstract Number: 0831
Sociodemographic, Disease, and Medication Profile of RA Patients Under 65 Years Compared with 65 Years or Older at Registry Enrollment: Real World Results from a Rheumatoid Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 0819
The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar
9:00AM-11:00AM
Abstract Number: 0801
The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study
9:00AM-11:00AM
Abstract Number: 0824
The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study
9:00AM-11:00AM
Abstract Number: 0805
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0808
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort
9:00AM-11:00AM
Abstract Number: 0816
Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
9:00AM-11:00AM
Abstract Number: 0813
Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Czech Registry ATTRA Treated with JAK Inhibitors
9:00AM-11:00AM
Abstract Number: 0817
Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia

« View all sessions from this meeting

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology